JNJ-10397049 (10-30 mg/kg) decreases the latency for persistent sleep and increased nonrapid eye movement and rapid eye movement sleep time[2].
JNJ-10397049 blocks ethanol self-administration, place preference and reinstatement[3].
| Animal Model: | Male Sprague-Dawley rats[2]. |
| Dosage: | 10 mg/kg. |
| Administration: | Subcutaneous administration. |
| Result: | Induced a significant reduction in NREM sleep latency and an increase in NREM sleep duration during the first 2 h after administration relative to vehicle treatment.
|
